⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1058243 | 0.84 | — | — | |
| SCHEMBL1078346 | 0.83 | SIGMAR1 (0.45) | — | |
| SCHEMBL1082831 | 0.76 | — | — | |
| SCHEMBL1050892 | 0.75 | — | — | |
| SCHEMBL1057330 | 0.75 | — | — | |
| SCHEMBL5927938 | 0.75 | — | — | |
| SCHEMBL1056021 | 0.74 | — | — | |
| SCHEMBL1056632 | 0.72 | — | — | |
| SCHEMBL1059182 | 0.71 | — | — | |
| SCHEMBL1058823 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204251-A1 | MOLECULAR TARGET OF NEUROTOXICITY | EXONHIT THERAPEUTICS SA (FR) | 2010-08-12 | — | — | US | claimed |
| EP-1982704-B1 | New molecular target of neurotoxicity | EXONHIT THERAPEUTICS SA (FR) | 2010-08-04 | — | — | EP | claimed |
| US-20060241062-A1 | Method involving pde4, compositions, and the screening thereof, for the treatment of degenerative ocular pathologies | EXONHIT THERAPEUTICS SA (FR) | 2006-10-26 | — | — | US | claimed |
| US-20060142326-A1 | Use of pyrazolopyridines for the treatment of cognitive deficits | DIAXONHIT (FR) | 2006-06-29 | — | — | US | claimed |
| US-20050043319-A1 | Detecting neuronal stress via monitoring in vitro expression of phosphodiesterases; diagnosis, prevention and treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; drug screening | EXONHIT THERAPEUTICS SA (FR) | 2005-02-24 | — | — | US | claimed |
| US-20040219552-A1 | Novel molecular target for neurotoxicity | EXONHIT THERAPEUTICS SA (FR) | 2004-11-04 | — | — | US | claimed |
| US-20120202846-A1 | MOLECULAR TARGET OF NEUROTOXICITY | EXONHIT THERAPEUTICS SA (FR) | 2012-08-09 | — | — | US | disclosed |
| US-7872015-B2 | Methods involving PDE4, compositions, and the screening thereof, for the treatment of degenerative ocular pathologies | EXONHIT THERAPEUTICS SA (FR) | 2011-01-18 | — | — | US | disclosed |
| US-20100204251-A1 | MOLECULAR TARGET OF NEUROTOXICITY | EXONHIT THERAPEUTICS SA (FR) | 2010-08-12 | — | — | US | disclosed |
| EP-1982704-B1 | New molecular target of neurotoxicity | EXONHIT THERAPEUTICS SA (FR) | 2010-08-04 | — | — | EP | disclosed |
| US-20090317842-A1 | Methods and Tools for The Therapy of Neurodegenerative Pathologies | EXONHIT THERAPEUTICS SA (FR) | 2009-12-24 | — | — | US | disclosed |
| EP-1417349-B1 | NOVEL MOLECULAR TARGET FOR NEUROTOXICITY | EXONHIT THERAPEUTICS SA (FR) | 2008-11-19 | — | — | EP | disclosed |
| EP-1982704-A2 | New molecular target of neurotoxicity | Exonhit Therapeutics SA (FR) | 2008-10-22 | — | — | EP | disclosed |
| US-20060241062-A1 | Method involving pde4, compositions, and the screening thereof, for the treatment of degenerative ocular pathologies | EXONHIT THERAPEUTICS SA (FR) | 2006-10-26 | — | — | US | disclosed |
| US-20060142326-A1 | Use of pyrazolopyridines for the treatment of cognitive deficits | DIAXONHIT (FR) | 2006-06-29 | — | — | US | disclosed |
| EP-1638559-A1 | USE OF PYRAZOLOPYRIDINES FOR THE TREATMENT OF COGNITIVE DEFICITS | Exonhit Therapeutics S.A. (FR) | 2006-03-29 | — | — | EP | disclosed |
| US-20050043319-A1 | Detecting neuronal stress via monitoring in vitro expression of phosphodiesterases; diagnosis, prevention and treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; drug screening | EXONHIT THERAPEUTICS SA (FR) | 2005-02-24 | — | — | US | disclosed |
| WO-2005000302-A1 | USE OF PYRAZOLOPYRIDINES FOR THE TREATMENT OF COGNITIVE DEFICITS | EXONHIT THERAPEUTICS SA (FR) | 2005-01-06 | — | — | WO | disclosed |
| US-20040219552-A1 | Novel molecular target for neurotoxicity | EXONHIT THERAPEUTICS SA (FR) | 2004-11-04 | — | — | US | disclosed |